

1 **Title:** Risk Factors Associated with Increased Antibiotic Use in COVID-19 Hospitalized Patients

2

3 **Authors:** Alysa J. Martin, PharmD¹#; Stephanie Shulder, PharmD, BCIDP¹; David Dobrzynski,
4 MD²; Katelyn Quartuccio, PharmD, BCPS³; Kelly E. Pillinger, PharmD, BCPS-AQ ID, BCIDP¹

5

6 ¹ University of Rochester Medical Center Strong Memorial Hospital, Department of Pharmacy,
7 Rochester, NY, USA

8 ² University of Rochester Medical Center, Division of Infectious Diseases, Rochester, NY, USA

9 ³ University of Rochester Medical Center Highland Hospital, Department of Pharmacy,
10 Rochester, NY, USA

11

12 **# Address correspondence to:** Alysa J. Martin, PharmD, alysa_martin@urmc.rochester.edu

13

14 **Running title:** COVID-19 antibiotic risk factors

15 **Key words:** COVID-19, antimicrobial stewardship, antibiotics, community-acquired pneumonia,
16 bacterial infection

17

18

19

20

21

22

23

24 **Abstract**

25 Literature suggests that antibiotic prescribing in COVID-19 patients is high, despite low
26 rates of confirmed bacterial infection. There are little data on what drives prescribing habits.
27 This retrospective, multi-center, observational study sought to determine antibiotic prescribing
28 rates and risk factors for antibiotic prescribing in hospitalized patients. Patients admitted from
29 March 1, 2020 to May 31, 2020 and treated for PCR-confirmed COVID-19 were included. The
30 primary endpoint was the rate of antibiotic use during hospitalization. Secondary endpoints
31 included risk factors associated with antibiotic use, risk factors associated with receiving more
32 than one antibiotic course, and rate of microbiologically confirmed infections. A total of 208
33 encounters (198 patients) were included in the final analysis. Eighty-three percent of patients
34 received at least one course of antibiotics, despite low rates of microbiologically confirmed
35 infection (12%). Almost one-third of patients (30%) received more than one course of
36 antibiotics. There was a low rate of respiratory cultures obtained (32%). Risk factors identified
37 in a univariate analysis for both antibiotic prescribing and receiving more than one course of
38 antibiotics were more serious illness, increased hospital length of stay, ICU admission,
39 mechanical ventilation, and ARDS. This study highlights the need for increased antibiotic
40 stewardship practices in COVID-19 patients. Further studies should be conducted to determine
41 the utility of different stewardship initiatives in COVID-19 patients.

42

43

44

45 Introduction

46 The novel coronavirus disease identified in 2019 (COVID-19) is caused by a
47 betacoronavirus known as SARS-CoV-2. Despite the fact that COVID-19 is a viral infection,
48 clinical manifestations may present similarly to a bacterial pneumonia.¹ Patients often present
49 with respiratory symptoms including fever, cough, dyspnea, and bilateral changes on chest
50 imaging.¹ It can be difficult to determine if patients have a bacterial respiratory coinfection
51 along with COVID-19 infection. This may lead to over-prescribing of antibiotics in patients with
52 COVID-19.

53 Despite bacterial coinfection being reported in 2-8% of patients, rates of antibiotic
54 prescribing have ranged from 57-95% in hospitalized patients.¹⁻⁷ Additionally, there are reports
55 of increased consumption of antibiotics during the COVID-19 pandemic.⁶⁻⁹ Over-prescribing of
56 antibiotics may increase the risk of adverse side effects, nosocomial infection, and antibiotic
57 resistance. Several organizational guidelines recommend starting empiric antibiotic therapy if
58 concern for bacterial pneumonia or sepsis, but to re-evaluate daily and de-escalate or
59 discontinue if no evidence of bacterial infection.¹⁰⁻¹⁴ Furthermore, they emphasize the
60 importance of antimicrobial stewardship programs which may help to avoid starting antibiotics
61 reflexively or continuing unnecessary courses. The World Health Organization (WHO) has
62 released guidance which discourages the use of antibiotic therapy for patients with COVID-19
63 infections unless signs and symptoms of a bacterial infection exist.¹¹

64 Unfortunately, there are limited data to date describing the need or role for antibiotics
65 in COVID-19 or outcomes for patients who receive them. Additionally, little is known regarding

66 risk factors associated with antibiotic use. There have only been two previous studies which
67 evaluated prescribing trends, and risk factors of antibiotic prescribing. Both studies focused on
68 prescribing rates, coinfections and risk factors associated with antibiotic prescribing within the
69 first 48 hours of admission.^{4,5}

70 The purpose of this study was to evaluate the rate of antibiotic use in COVID-19 patients
71 and risk factors associated with antibiotic use throughout hospitalization. A better
72 understanding of prescribing practices can be used to evaluate opportunities for antibiotic
73 stewardship for future patients with COVID-19.

74 **Methods**

75 *Study design*

76 This was a multi-center, retrospective, observational study of antibiotic prescribing
77 trends in patients with confirmed COVID-19 at three hospitals within the University of
78 Rochester Medical Center.

79 Patients 18 years and older admitted from March 1, 2020 to May 31, 2020 and treated
80 for PCR-confirmed COVID-19 were eligible for inclusion. Patients did not meet inclusion criteria
81 if they were only treated in the emergency department without subsequent admission. Patients
82 could be included more than once if they had multiple admissions within the study period.

83 Patients were excluded if they were asymptomatic. Data were collected until June 30, 2020.

84 This study was reviewed and deemed exempt by the Institutional Review Board.

85 *Data Collection*

86 Patients were identified from the electronic health record based on a positive or
87 presumptive positive SARS-CoV-2 PCR test. Baseline data including age, gender, race, weight,
88 height, comorbidities, date of first positive SARS-CoV-2 PCR, and admission and discharge dates
89 were collected. Labs on admission (or at time of positive test if nosocomial transmission),
90 microbiologic data, clinical symptoms, imaging, antibiotic data, COVID-19 investigational or off-
91 label treatment, death and re-admission within 30 days were also collected.

92 *Outcomes*

93 The primary endpoint of the study was the rate of antibiotic use in patients admitted for
94 COVID-19. Secondary endpoints included risk factors associated with antibiotic use, risk factors
95 associated with receiving more than one antibiotic course, and rate of microbiologically-
96 confirmed infections.

97 *Statistical Analysis*

98 Data were analyzed using R statistical software version 4.0.2 (Boston, MA) with a p-
99 value < 0.05 considered statistically significant. Continuous variables were described using a
100 median with interquartile range (IQR). Categorical variables were analyzed using Fisher's exact
101 testing. Two-sample Wilcoxon test was used for continuous variables. To evaluate risk factors
102 associated with antibiotic use, a univariate analysis was conducted and variables with a p-value
103 ≤ 0.05 were included in a multivariate logistic regression. In addition, a univariate analysis and
104 multivariate logistic regression were conducted for patients receiving more than one course of
105 antibiotics with the following pre-specified variables included if $P < 0.05$ and clinically
106 significant: length of stay, intensive care unit (ICU) admission, ICU length of stay, mechanical

107 ventilation, more than one COVID-19 related admission, microbiologically-confirmed infection,
108 time from SARS-CoV-2 collection date to initial antibiotic start, and 28-day mortality.

109

110 **Results:**

111 A total of 228 encounters met inclusion criteria, with twenty excluded due to
112 asymptomatic disease, leaving 208 encounters included in the final analysis (n=198 patients).
113 The median age was 69 years (IQR 60-80) and 50% (105/208) were male (Table 1). The most
114 common comorbidities were hypertension (143/208, 69%), obesity (81/208, 39%), and diabetes
115 (81/208, 39%). Of 208 encounters, 83% of patients received at least one course of antibiotics.
116 Antibiotic prescribing did not differ based on gender, age, race, or comorbidities. Even though a
117 small subset of patients (n=11), all immunocompromised patients received antibiotics (Table 1).

118 While rates of antibiotic prescribing overall were high, we saw a temporal decrease in
119 antibiotic prescribing. When consolidating encounters by month of admission, rates of
120 antibiotic prescribing were highest in March, with 88% (42/49) of encounters receiving
121 antibiotics, compared to 82% (127/155) in April and 75% (3/4) in May.

122 Rates of antibiotic prescribing were significantly higher in patients admitted to the ICU,
123 requiring O2 support (including ventimask, BiPAP and mechanical ventilation), and with acute
124 respiratory distress syndrome (ARDS) ($p < 0.0001$). Median length of stay was 6.5 days longer in
125 those receiving antibiotics ($p < 0.0001$). Patients who received investigational or off-label
126 therapy for COVID-19 were also more often prescribed antibiotics ($p = 0.0328$). Of patients who
127 died within 28 days, 92% received antibiotics (47/51, $p=0.017$). Additionally, median aspartate

128 transaminase (AST), lactate dehydrogenase (LDH), and procalcitonin (PCT) at baseline were
129 higher in those who were prescribed antibiotics (Table 1). PCT > 0.5 was associated with a
130 higher rate of antibiotic prescribing [94% (44/47) prescribed antibiotics vs. 6% (3/47) did not
131 receive antibiotics, OR 3.76, CI 1.09-20.1, p = 0.03]. Of patients with a PCT > 0.5, 43/47 had
132 respiratory or blood cultures obtained. Microbiologically confirmed bacterial infection was
133 present in 12% (5/43).

134 Respiratory cultures were obtained in 32% (67/208) of patients. In total, 19% (13/67)
135 were positive (Table 2). *Staphylococcus aureus* was identified in 5 (38%) of 13 positive
136 respiratory culture results (3% of total patients). Blood cultures were obtained in the majority
137 of patients (149/208, 72%), but few were positive (12/149, 7%). All influenza PCR and *Legionella*
138 urinary antigen (UAg) tests were negative. Two *Streptococcus pneumoniae* UAg tests were
139 positive (2.4%, 2/84). In addition, 75 patients (36%) were screened for MRSA nares
140 colonization. Overall, there were 24 microbiologically-confirmed infections treated with
141 antibiotics [11% (24/208) overall]. In a subgroup analysis, patients with microbiologically
142 confirmed infections were more likely to receive more than one course of antibiotics, be
143 admitted to the ICU, and have a longer length of stay.

144 The most frequently prescribed initial antibiotics were ceftriaxone in 113 (66%) patients
145 and azithromycin in 99 (57%) patients for community acquired pneumonia (CAP), followed by
146 an anti-pseudomonal beta lactam (23%) and vancomycin (23%) for hospital acquired
147 pneumonia (HAP) or ventilator associated (VAP) (Figures 1 and 2). The median time from SARS-
148 CoV-2 collection to antibiotic initiation was one day (IQR 1-4.5 days). Median duration of
149 therapy for the initial course of antibiotics was five days (IQR 2-6 days). In 41 (24%) patients,

150 the initial regimen was changed; 17 patients were escalated to broader therapy (42%) and 15
151 patients were de-escalated to narrower therapy (37%). Nine (22%) had another regimen change
152 such as intravenous to oral conversion or changed to another agent with similar spectrum of
153 activity.

154 Fifty-two patients (30%) received a second course of antibiotics and 19 patients (11%)
155 received more than 2 antibiotic courses during hospitalization. The most frequently prescribed
156 antibiotics included an anti-pseudomonal beta lactam (58%) and vancomycin (58%) for
157 HAP/VAP (Figures 1 and 2). The median duration of second course antibiotics was 6 days (IQR 3-
158 8.25). Duration of admission, ICU admission, ICU LOS, mechanical ventilation, microbiologically
159 confirmed infection, and duration of initial course of antibiotics were all risk factors for
160 receiving more than one course of antibiotics (Table 3). Based on the number of patients
161 receiving more than one course of antibiotics, and of the variables that were both statistically
162 significant and clinically relevant on univariate analysis, we chose to include ICU admission,
163 mechanical ventilation, microbiologically confirmed infection, duration of admission and ICU
164 LOS in our multivariate analysis. ICU length of stay was the only variable found to be a
165 statistically significant in the multivariate analysis. (Table 4).

166 **Discussion**

167 In this multi-center study of patients hospitalized with COVID-19, we found an overall
168 high rate of antibiotic prescribing, with 83% of patients receiving antibiotics. Of these patients,
169 30% received at least one additional course of antibiotics during hospitalization, increasing the
170 overall antibiotic exposure. Despite the high rate of antibiotic prescribing, there were low rates

171 of bacterial coinfection, with only 12% of patients having microbiologically confirmed infection.
172 These findings are similar to the results of previous studies, suggesting the need for strategies
173 to help clinicians judiciously prescribe antibiotics in patients with COVID-19.^{1-5,15} Interestingly,
174 while still low, our rate of bacterial coinfection was higher compared to other US studies.
175 Compared to these previous studies, we had higher rates of ICU admission and mechanically
176 ventilated patients.^{4,5} In our study, we reported microbiologic data throughout hospitalization,
177 and even during multiple admissions whereas these two previous studies only reported the first
178 48 hours. This likely contributed to higher rates of microbiologically confirmed infections in our
179 study. Patients with microbiologically confirmed infections were more likely to receive more
180 than one course of antibiotics, be admitted to the ICU, and have a longer length of stay. While
181 this may suggest patients with bacterial coinfection are more likely to have serious illness, the
182 higher rate of microbiologically confirmed infections may also be explained by bacterial
183 infections acquired during hospitalization. Additional courses of antibiotics were often
184 prescribed for empiric or targeted treatment of nosocomial infection.

185 Early in the pandemic, little was known regarding COVID-19 presentation and disease
186 progression. Additionally, there was a paucity of data suggesting bacterial co-infection was low
187 in the beginning of the COVID-19 pandemic. Thus, guideline recommendations were evolving
188 throughout the study period. Initial recommendations often encouraged antibiotic use. Within
189 the University of Rochester Medical Center, our practices and institutional guidelines
190 recommended initiating empiric antibiotics in the majority of COVID-19 patients. As information
191 became more available, and recommendations changed, our antibiotic prescribing decreased.

192 This was reflected in the temporal decline in antibiotic prescribing we observed from March to
193 May.

194 There were several indicators that serious illness increased the risk of antibiotic
195 prescribing. Initial antibiotic prescribing was more likely in patients with certain elevated
196 laboratory values (PCT, AST, and LDH), longer length of stay, ICU admission, longer ICU length of
197 stay, and administration of off-label or investigational therapy for COVID-19. Additionally, all
198 patients with ARDS or requiring more invasive O2 support received at least 1 course of
199 antibiotics. These findings are consistent with previous studies which found patients were more
200 likely to receive antibiotics if they had severe disease upon presentation.^{4,5} To our knowledge,
201 this is the first study to report rates of additional antibiotic prescribing beyond initial empiric
202 therapy. Patients with COVID-19 often have a prolonged hospitalization due to the underlying
203 disease process. Our median LOS was significantly longer in patients which received at least one
204 antibiotic course ($p < 0.001$), and prolonged hospitalization may also increase the potential for
205 additional antibiotic exposure. Thus, it is important to understand antibiotic prescribing trends
206 and associated risk factors beyond the first course. Our study found that nearly one-third of all
207 patients received two or more courses of antibiotics. Variables associated with receiving two or
208 more antibiotic courses included: longer length of stay, ICU admission, longer ICU length of
209 stay, and mechanical ventilation. This is likely explained as these are all risk factors for hospital-
210 acquired illness and antibiotics were commonly prescribed for nosocomial infection (e.g.
211 HAP/VAP).

212 Procalcitonin has been suggested as a potentially useful biomarker to differentiate
213 bacterial and viral infections and assist with clinical decision-making. A Cochrane review of

214 acute respiratory infections concluded that use of procalcitonin to guide treatment decisions
215 results in lower antibiotic consumption, lower mortality, and fewer antibiotic-related side
216 effects.¹⁶ In contrast, a recent study in pneumonia comparing procalcitonin-guided treatment
217 and usual care found no difference in duration of antibiotic treatment or antibiotic-associated
218 outcomes.¹⁷ The ATS/IDSA CAP guidelines strongly advise initiating antibiotics based off clinical
219 judgement rather than procalcitonin alone.¹³ In COVID-19 patients specifically, a recent
220 retrospective cohort study found that patients with COVID-19 consistently had negative
221 procalcitonin levels (< 0.25 ng/mL).¹⁸ Conversely, elevated procalcitonin levels have been
222 associated with severity of illness or mortality.¹⁹ Elevated procalcitonin may represent bacterial
223 coinfection, but could also be due to immune dysregulation.²⁰ At our sites, the patients
224 prescribed antibiotics had significantly higher baseline procalcitonin, however the median was
225 only 0.28. In a subgroup analysis focusing on patients who had a procalcitonin of > 0.5, 94% of
226 patients received antibiotics. It is unclear at this time the utility of using procalcitonin to
227 determine if there is bacterial co-infection with COVID-19.

228 Previous studies have shown high rates of broad-spectrum antibiotics for initial empiric
229 therapy in COVID-19 patients.^{1,3-6,8,15} However, in our patient population, most patients were
230 treated initially for CAP. The most common agents included ceftriaxone plus azithromycin,
231 which is consistent with the 2019 ATS/IDSA recommendations for CAP.¹³ During the initial
232 antibiotic course, 36.6% of patients were de-escalated to narrower therapy. Not surprisingly,
233 patients that received a second course of antibiotics were more likely to receive broad-
234 spectrum antimicrobials; over half of patients who received more than one course of antibiotics
235 were treated for HAP/VAP and prescribed an anti-pseudomonal beta lactam (i.e cefepime or

236 piperacillin/tazobactam.) Respiratory cultures were obtained in only 30.2% of patients, with a
237 large number of patients receiving empiric treatment for CAP, HAP or VAP. In part, the low
238 number of respiratory cultures obtained may be due to the symptomatology of disease, with
239 the majority of patients experiencing dry, non-productive cough.¹ Additionally, early in the
240 pandemic, there were concerns regarding transmission and aerosolization, which added
241 additional challenges to obtaining respiratory cultures. In addition, the 2019 ATS/IDSA CAP
242 guidelines do not recommend routine sputum gram stain and culture in patients with non-
243 severe CAP or those without multi-drug resistant organism risk factors due to overall poor yield
244 and detection of organisms.¹³ However, respiratory cultures are recommended in patients
245 being treated empirically for MDR organisms, and in those being treated for HAP/VAP.^{13,14}
246 Respiratory cultures were not obtained in all patients who met these criteria. Obtaining
247 respiratory cultures and other microbiologic data, when possible, on patients treated with
248 broad spectrum antibiotics can potentially help with de-escalation of therapy.

249 One limitation of this study is its retrospective design. Laboratory and microbiologic
250 data collected were not consistent amongst all patients. We found duration of admission and
251 ICU length of stay to be associated with higher antibiotic use, however it is difficult to say that
252 these are true risk factors for antibiotic prescribing. Instead, this difference was likely due to
253 antibiotic prescribing being higher in patients with more serious illness, and perhaps longer
254 admission leading to increased risk of nosocomial infections and subsequent antibiotic courses.
255 Additionally, we did not perform a time adjusted analysis. Another limitation is that the vast
256 majority of patients within our study received antibiotics which could have affected our ability
257 to detect differences between the two groups.

258 While there were limitations of this study, there were also several strengths. This study
259 was multi-site, including three hospitals within the University of Rochester Medical Center: two
260 community hospitals and a tertiary academic medical center. Therefore, the results of this
261 study may be generalizable to similar sites. Finally, as previously mentioned, this is the first
262 study to assess overall antibiotic use throughout hospitalization, and determine risk factors for
263 additional antibiotic courses. Many patients with COVID-19 have prolonged hospitalization,
264 increasing the risk for antibiotic exposure. Our study examined antibiotic use that is more
265 representative of hospitalized COVID-19 patients.

266 **Conclusions**

267 Our study found high rates of antibiotic prescribing, despite low rates of respiratory
268 cultures and confirmed microbiologic infections. Antibiotic prescribing was higher in patients
269 with elevated PCT, longer LOS, ICU admission, 28-day mortality, investigational or off-label
270 treatment for COVID-19, ARDS, and invasive O2 support. Nearly one-third of patients were
271 treated with more than one antibiotic course during hospitalization. Patients who received two
272 or more antibiotic courses were more likely to have longer ICU LOS as demonstrated by the
273 multivariate analysis. These data highlight a role for antimicrobial stewardship during the
274 COVID-19 pandemic. Further studies are needed to examine the impact of antimicrobial
275 stewardship initiatives in patients with COVID-19 and assess if antibiotic prescribing practices
276 have changed with increasing information related to bacterial co-infection that wasn't available
277 at the beginning of the pandemic.

278

279 **Acknowledgements**

280 The authors thank Raquel Roberts, PharmD for her assistance with data collection. There was

281 no funding for the study. The authors report no conflict of interest.

282 **Tables and Figures**

Baseline Characteristic	Total	Antibiotics n=172	No Antibiotics n=36	P-value
Male gender	105 (50.5)	84 (48.8)	21 (55.6)	0.43
Age, years (median, IQR)	69.0 (60-80)	70.0 (61-81)	65.5 (47-77)	0.12
Race				0.56
Caucasian	116 (55.7)	98 (56.9)	18 (47.2)	
Black/African American	69 (33.2)	53 (30.8)	16 (44.4)	
Asian	2 (1.0)	2 (1.2)	0 (0)	
Other	6 (2.9)	6 (3.5)	0 (0)	
Unknown	15 (7.2)	13 (7.6)	2 (5.6)	
Comorbidities				
Hypertension	143 (68.8)	116 (67.4)	27 (72.2)	0.43
Diabetes	81 (38.9)	70 (23.2)	11 (27.8)	0.35
Obesity	80 (38.5)	66 (38.4)	14 (38.9)	>0.99
Cardiac Disease	56 (26.9)	50 (29.1)	6 (16.7)	0.15
Chronic Lung Disease	43 (20.7)	37 (21.5)	6 (16.7)	0.65
CKD	45 (21.7)	40 (23.2)	5 (13.9)	0.20
None	21 (10.1)	17 (9.9)	4 (11.1)	0.77
Immunocompromised ^a	11 (5.3)	11 (6.4)	0 (0)	0.22
Labs (median, IQR)				
AST, U/L	43 (31-65)	46 (33.25-65)	35 (26.75-49)	0.02
ALT, U/L	30 (20-46)	29.5 (20-45)	32.5 (20-49.5)	0.83
Scr, mg/dL	1.130 (0.84-1.64)	1.14 (0.84-1.725)	1.06 (0.81-1.3)	0.14
WBC	7.30 (5.50-10.50)	7.4 (5.5-10.7)	6.8 (4.8-9.2)	0.11
ALC	1.0 (0.7-1.3)	1.0 (0.7-1.3)	1.1 (0.5-1.4)	0.10
CRP	93.0 (39.5-134.5)	93 (39.5-134.5)	73 (37.5-118.5)	0.37
LDH	344 (264.5-467)	348 (285-474)	294 (239-387)	0.03
Ferritin	627 (304-1086)	627 (309-1133.5)	589 (235-980)	0.45

D-dimer	1.26 (0.63-2.08)	1.37 (0.71-2.1)	0.86 (0.6-1.6)	0.24
PCT	0.215 (0.120-0.620)	0.28 (0.13-0.63)	0.13 (0.09-0.20)	<0.01
Symptoms Prior to Admission				
Fever	120 (57.7)	101 (58.7)	19 (52.8)	0.59
Respiratory Symptoms	180 (86.5)	152 (88.4)	28 (75)	0.10
Gastrointestinal symptoms	76 (36.5)	60 (34.9)	16 (41.7)	0.34
Anosmia/Hyposmia/Hypogeusia	11 (5.3)	10 (5.8)	1 (2.8)	0.69
Symptom duration prior to admission, days (median, IQR)	6.0 (3-9)	6.0 (3-9)	7.5 (4.75-9)	0.16
Location prior to admit				
Home	140 (67.3)	110 (63.9)	30 (80.5)	
SNF	60 (28.8)	54 (31.4)	6 (16.7)	
Transfer from OSH	8 (3.8)	8 (4.7)	0 (0)	
Duration of admission, days (median, IQR)	11 (5-22)	12 (5.75-25)	5.5 (4-11.3)	<0.01
ICU admission	104	102 (58.9)	2 (5.6)	<0.01
ICU LOS, days (median, IQR)	10 (3-18)	10 (3.25-18)	6.5 (6.25-6.75)	0.59
O2 support				
Room Air	40 (19.2)	24 (13.9)	16 (44.4)	
Standard Nasal Cannula	67 (32.2)	49 (28.5)	18 (50.0)	
HFNC/Venti Mask	19 (9.1)	17 (9.9)	2 (5.6)	
BiPAP	5 (2.4)	5 (2.9)	0 (0)	
Non-rebreather	7 (3.4)	7 (4.1)	0 (0)	
Mechanical ventilation	70 (33.7)	70 (40.7)	0 (0)	
ARDS	78 (37.5)	78 (45.3)	0 (0)	<0.01
Received investigational or off-label transfer for COVID-19	37 (17.8)	35 (20.2)	2 (5.6)	0.03
28-day mortality	51 (24.5)	48 (27.9)	3 (8.3)	0.02
30-day readmission	16 (7.7)	12 (6.9)	4 (11.1)	0.75
More than 1 admission for COVID-19	12 (5.8)	8 (4.7)	4 (11.1)	0.23
Time from discharge to COVID-19 readmission, days (median, IQR)	7 (4.5-12.25)	5 (2.75-11.5)	10 (7.75-12.5)	0.22

283 (= Percentages unless otherwise specified
284 a = immunocompromised patients were defined as those with previous solid organ transplant,
285 active cancer receiving chemotherapy, patients on biologic therapy, and uncontrolled HIV
286 IQR = Interquartile Range
287 CKD = chronic kidney disease
288 AST = Aspartate aminotransferase
289 ALT = Alanine aminotransferase
290 SCr = Serum Creatinine
291 WBC = White blood cell count
292 ALC = Absolute lymphocyte count
293 CRP = C-reactive protein
294 LDH = Lactate dehydrogenase
295 PCT = procalcitonin
296 SNF = Skilled nursing facility
297 HFNC = high flow nasal cannula
298 Respiratory symptoms were defined as hypoxia, SOB, cough

299 GI symptoms were defined as nausea, vomiting, diarrhea

300


301

302

Table 2: Microbiologic Data			
Micro Data	Antibiotics n=172	No antibiotics n=36	P-value
Microbiologically-confirmed infection	24 (14.0)	0 (0)	0.02
Respiratory cultures obtained	66 (38.3)	1 (2.7)	<0.01
No growth	53 [80.3]	1 [100]	>0.99
Positive	13 [19.7]	0 [0]	>0.99
Blood cx obtained	135 (78.5)	14 (38.9)	<0.01
No growth	123 [91.1]	14 [100]	0.61
Positive	12 [8.9]	0 [0]	0.61
Influenza PCR obtained	75 (43.6)	13 (36.1)	0.46
Strep pneumoniae urinary antigen obtained	82 (47.7)	6 (16.7)	<0.01
Positive	2 [2.4]	0 [0]	>0.99
Negative	80 [97.6]	6 [100]	>0.99
Legionella urinary antigen obtained	87 (50.5)	6 (16.7)	<0.01
MRSA nares obtained	73 (42.4)	2 (5.6)	<0.01
Positive	4 [5.5]	0 [0]	>0.99
Negative	69 [94.5]	2 [100]	>0.99

303 (=) = percent unless otherwise specified


Figure 1: Antibiotic Prescribing Trends



304

305

Figure 2: Indications for Antibiotic Prescribing



306

307

Table 3: Risk factors associated with receiving more than 1 course of antibiotics						
Variable	Univariate Analysis			Multivariate analysis		
	1 antibiotic course n= 120 (%)	> 1 antibiotic course n=52 (%)	P value	Odds ratio	95% CI	P-value
Length of stay, days (median, IQR)	8 (4-15)	25 (18.75-37)	<0.01	1.01	0.99-1.04	0.32
ICU admission	51 (42.5)	49 (94.2)	<0.01	1.96	0.38-11.10	0.42
ICU length of stay, days (median, IQR)	5 (3-9)	18 (12-26)	<0.01	1.14	1.06-1.26	<0.01
Mechanical ventilation	25 (20.8)	45 (86.5)	<0.01	1.83	0.46-7.61	0.39
More than 1 COVID-19 related admission	7 (5.8)	1 (1.9)	0.44			
Microbiologically-confirmed infection	4 (3.3)	20 (38.5)	<0.01	3.31	0.86-15.26	0.10
Duration of initial course of antibiotics, days (median, IQR)	4 (2-5.25)	5 (4-7)	<0.01			
Time from SARS-CoV-2 collect date	1 (0-5)	2 (0-2)	0.51			

to initial antibiotic start, days (median, IQR)						
28-day mortality	33 (27.5)	14 (38.9)	>0.99			

308 (= Percentages unless otherwise specified

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333 **References:**

- 334 1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with
335 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* (London, England) 2020;395:1054-62.
- 336 2. Crotty MP, Dominguez EA, Akins R, et al. Investigation of subsequent and co-infections
337 associated with SARS-CoV-2 (COVID-19) in hospitalized patients. medRxiv 2020.
- 338 3. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with
339 coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. *Clinical infectious diseases* :
340 an official publication of the Infectious Diseases Society of America 2020.
- 341 4. Vaughn VM, Gandhi T, Petty LA, et al. Empiric Antibacterial Therapy and Community-onset
342 Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study. 2020.
- 343 5. Wei W, Ortwine JK, Mang NS, Joseph C, Hall BC, Prokesch BC. Limited Role for Antibiotics in
344 COVID-19: Scarce Evidence of Bacterial Coinfection. Available at SSRN 3622388 2020.
- 345 6. Beović B, Doušak M, Ferreira-Coimbra J, et al. Antibiotic use in patients with COVID-19: a
346 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey. *Journal of Antimicrobial*
347 *Chemotherapy* 2020.
- 348 7. Buehrle DJ, Decker BK, Wagener MM, et al. Antibiotic consumption and stewardship at a
349 hospital outside of an early Coronavirus disease 2019 epicentre. 2020:AAC.01011-20.
- 350 8. Abelenda-Alonso G, Padullés A, Rombauts A, et al. Antibiotic prescription during the COVID-19
351 pandemic: A biphasic pattern. *Infection Control & Hospital Epidemiology* 2020:1-2.
- 352 9. Nestler M, Godbout E, Lee K, et al. Impact of COVID-19 on Pneumonia-Focused Antibiotic Use at
353 an Academic Medical Center. *Infection control and hospital epidemiology* 2020:1-9.
- 354 10. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment
355 Guidelines. National Institutes of Health
- 356
- 357 11. Clinical management of COVID-19 Interim Guidance - May 2020. World Health Organization.
358 2020, at <https://www.who.int/publications-detail/clinical-management-of-covid-19>.)
- 359 12. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the
360 management of critically ill adults with Coronavirus Disease 2019 (COVID-19). *Intensive care medicine*
361 2020;46:854-87.
- 362 13. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-
363 acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and
364 Infectious Diseases Society of America. 2019;200:e45-e67.
- 365 14. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and
366 Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of
367 America and the American Thoracic Society. *Clinical Infectious Diseases* 2016;63:e61-e111.
- 368 15. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic
369 review and meta-analysis. *The Journal of infection* 2020;81:266-75.
- 370 16. Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute
371 respiratory tract infections. *The Cochrane database of systematic reviews* 2017;10:Cd007498.
- 372 17. Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-Guided Use of Antibiotics for Lower
373 Respiratory Tract Infection. 2018;379:236-49.
- 374 18. Bass J, Singh A, Williams R, Lindner DH. Procalcitonin and COVID-19: A Reliable Clinical Tool.
375 2020.
- 376 19. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. *International journal*
377 *of antimicrobial agents* 2020;56:106051.
- 378 20. Shah V. *Advances in Motion* 2020.

379

380

381

382

383

Tables and Figures

Baseline Characteristic	Total	Antibiotics n=172	No Antibiotics n=36	P-value
Male gender	105 (50.5)	84 (48.8)	21 (55.6)	0.43
Age, years (median, IQR)	69.0 (60-80)	70.0 (61-81)	65.5 (47-77)	0.12
Race				0.56
Caucasian	116 (55.7)	98 (56.9)	18 (47.2)	
Black/African American	69 (33.2)	53 (30.8)	16 (44.4)	
Asian	2 (1.0)	2 (1.2)	0 (0)	
Other	6 (2.9)	6 (3.5)	0 (0)	
Unknown	15 (7.2)	13 (7.6)	2 (5.6)	
Comorbidities				
Hypertension	143 (68.8)	116 (67.4)	27 (72.2)	0.43
Diabetes	81 (38.9)	70 (23.2)	11 (27.8)	0.35
Obesity	80 (38.5)	66 (38.4)	14 (38.9)	>0.99
Cardiac Disease	56 (26.9)	50 (29.1)	6 (16.7)	0.15
Chronic Lung Disease	43 (20.7)	37 (21.5)	6 (16.7)	0.65
CKD	45 (21.7)	40 (23.2)	5 (13.9)	0.20
None	21 (10.1)	17 (9.9)	4 (11.1)	0.77
Immunocompromised ^a	11 (5.3)	11 (6.4)	0 (0)	0.22
Labs (median, IQR)				
AST, U/L	43 (31-65)	46 (33.25-65)	35 (26.75-49)	0.02
ALT, U/L	30 (20-46)	29.5 (20-45)	32.5 (20-49.5)	0.83
Scr, mg/dL	1.130 (0.84-1.64)	1.14 (0.84-1.725)	1.06 (0.81-1.3)	0.14
WBC	7.30 (5.50-10.50)	7.4 (5.5-10.7)	6.8 (4.8-9.2)	0.11
ALC	1.0 (0.7-1.3)	1.0 (0.7-1.3)	1.1 (0.5-1.4)	0.10
CRP	93.0 (39.5-134.5)	93 (39.5-134.5)	73 (37.5-118.5)	0.37
LDH	344 (264.5-467)	348 (285-474)	294 (239-387)	0.03
Ferritin	627 (304-1086)	627 (309-1133.5)	589 (235-980)	0.45
D-dimer	1.26 (0.63-2.08)	1.37 (0.71-2.1)	0.86 (0.6-1.6)	0.24
PCT	0.215 (0.120-0.620)	0.28 (0.13-0.63)	0.13 (0.09-0.20)	<0.01
Symptoms Prior to Admission				
Fever	120 (57.7)	101 (58.7)	19 (52.8)	0.59
Respiratory Symptoms	180 (86.5)	152 (88.4)	28 (75)	0.10

Gastrointestinal symptoms	76 (36.5)	60 (34.9)	16 (41.7)	0.34
Anosmia/Hyposmia/Hypogeusia	11 (5.3)	10 (5.8)	1 (2.8)	0.69
Symptom duration prior to admission, days (median, IQR)	6.0 (3-9)	6.0 (3-9)	7.5 (4.75-9)	0.16
Location prior to admit				0.08
Home	140 (67.3)	110 (63.9)	30 (80.5)	
SNF	60 (28.8)	54 (31.4)	6 (16.7)	
Transfer from OSH	8 (3.8)	8 (4.7)	0 (0)	
Duration of admission, days (median, IQR)	11 (5-22)	12 (5.75-25)	5.5 (4-11.3)	<0.01
ICU admission	104	102 (58.9)	2 (5.6)	<0.01
ICU LOS, days (median, IQR)	10 (3-18)	10 (3.25-18)	6.5 (6.25-6.75)	0.59
O2 support				<0.01
Room Air	40 (19.2)	24 (13.9)	16 (44.4)	
Standard Nasal Cannula	67 (32.2)	49 (28.5)	18 (50.0)	
HFNC/Venti Mask	19 (9.1)	17 (9.9)	2 (5.6)	
BiPAP	5 (2.4)	5 (2.9)	0 (0)	
Non-rebreather	7 (3.4)	7 (4.1)	0 (0)	
Mechanical ventilation	70 (33.7)	70 (40.7)	0 (0)	
ARDS	78 (37.5)	78 (45.3)	0 (0)	<0.01
Received investigational or off-label transfer for COVID-19	37 (17.8)	35 (20.2)	2 (5.6)	0.03
28-day mortality	51 (24.5)	48 (27.9)	3 (8.3)	0.02
30-day readmission	16 (7.7)	12 (6.9)	4 (11.1)	0.75
More than 1 admission for COVID-19	12 (5.8)	8 (4.7)	4 (11.1)	0.23
Time from discharge to COVID-19 readmission, days (median, IQR)	7 (4.5-12.25)	5 (2.75-11.5)	10 (7.75-12.5)	0.22

(%) = Percentages unless otherwise specified

a = immunocompromised patients were defined as those with previous solid organ transplant, active cancer receiving chemotherapy, patients on biologic therapy, and uncontrolled HIV

IQR = Interquartile Range

CKD = chronic kidney disease

AST = Aspartate aminotransferase

ALT = Alanine aminotransferase

SCr = Serum Creatinine

WBC = White blood cell count

ALC = Absolute lymphocyte count

CRP = C-reactive protein

LDH = Lactate dehydrogenase

PCT = procalcitonin

SNF = Skilled nursing facility

HFNC = high flow nasal cannula

Respiratory symptoms were defined as hypoxia, SOB, cough

GI symptoms were defined as nausea, vomiting, diarrhea

Table 2: Microbiologic Data			
Micro Data	Antibiotics n=172	No antibiotics n=36	P-value
Microbiologically-confirmed infection	24 (14.0)	0 (0)	0.02
Respiratory cultures obtained	66 (38.3)	1 (2.7)	<0.01
No growth	53 [80.3]	1 [100]	>0.99
Positive	13 [19.7]	0 [0]	>0.99
Blood cx obtained	135 (78.5)	14 (38.9)	<0.01
No growth	123 [91.1]	14 [100]	0.61
Positive	12 [8.9]	0 [0]	0.61
Influenza PCR obtained	75 (43.6)	13 (36.1)	0.46
Strep pneumoniae urinary antigen obtained	82 (47.7)	6 (16.7)	<0.01
Positive	2 [2.4]	0 [0]	>0.99
Negative	80 [97.6]	6 [100]	>0.99
Legionella urinary antigen obtained	87 (50.5)	6 (16.7)	<0.01
MRSA nares obtained	73 (42.4)	2 (5.6)	<0.01
Positive	4 [5.5]	0 [0]	>0.99
Negative	69 [94.5]	2 [100]	>0.99

()= percent unless otherwise specified

[]= percent of subset

Figure 1: Antibiotic Prescribing Trends





Figure 2: Indications for Antibiotic Prescribing



Variable	Univariate Analysis			Multivariate analysis		
	1 antibiotic course n= 120 (%)	> 1 antibiotic course n=52 (%)	P value	Odds ratio	95% CI	P-value
Length of stay, days (median, IQR)	8 (4-15)	25 (18.75-37)	<0.01	1.01	0.99-1.04	0.32
ICU admission	51 (42.5)	49 (94.2)	<0.01	1.96	0.38-11.10	0.42
ICU length of stay, days (median, IQR)	5 (3-9)	18 (12-26)	<0.01	1.14	1.06-1.26	<0.01
Mechanical ventilation	25 (20.8)	45 (86.5)	<0.01	1.83	0.46-7.61	0.39
More than 1 COVID-19 related admission	7 (5.8)	1 (1.9)	0.44			
Microbiologically-confirmed infection	4 (3.3)	20 (38.5)	<0.01	3.31	0.86-15.26	0.10
Duration of initial course of antibiotics, days (median, IQR)	4 (2-5.25)	5 (4-7)	<0.01			
Time from SARS-CoV-2 collect date to initial antibiotic start, days (median, IQR)	1 (0-5)	2 (0-2)	0.51			
28-day mortality	33 (27.5)	14 (38.9)	>0.99			

()= Percentages unless otherwise specified